Based on the assumption that Enzalutamide (Xtandi) is approved for use in men with castrate resistant metastatic prostate cancer (advanced prostate cancer or mCRPC) who have not had prior chemotherapy, pretty much a foregone conclusion based on the extraordinary phase III Prevail Trial results, including a statistically significant survival advantage of 2.2 months with a [...]
Is the FDA softening their stance on approving drugs using progression radiographic progression-free survival (rPFS) (how long it takes for the disease to progress based on scans) as opposed to only survival? The answer is maybe, under certain circumstances. An article in Clinical Cancer Research looked into the US Food and Drug Administration’s thinking about [...]
You have cancer and now you need to add a new battle, with your insurance company because they have denied your request to cover a certain drug or a treatment. Going to your health insurer is always frustrating and time-consuming. They don't care if what you need will extend your life or make living better, [...]
It is probably still years off, but it is worth watching. Galetrone (TOK-001) has just completed phase II trials with the results scheduled to be released at ASCO-GU at the end of the month. I will be attending this conference and will be present for their presentation and report it to you from the conference. [...]
One of the common and constant complaints I hear at prostate cancer support groups is about the need to wake during the night and use the bathroom to urinate (nocturia). There is a relationship between our ageing and the need to urinate at night, but it does seem to be made even more acute if [...]